Total Payments
$47,159
2024 Payments
$188.11
Companies
37
Transactions
417
Medicare Patients
1,732
Medicare Billing
$164,008
Payment Breakdown by Category
Research$41,337 (87.7%)
Food & Beverage$5,459 (11.6%)
Consulting$267.00 (0.6%)
Education$73.17 (0.2%)
Other$23.70 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $41,337 | 6 | 87.7% |
| Food and Beverage | $5,459 | 406 | 11.6% |
| Consulting Fee | $267.00 | 1 | 0.6% |
| Education | $73.17 | 2 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23.70 | 2 | 0.1% |
Payments by Type
Research
$41,337
6 transactions
General
$5,823
411 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $41,337 | 6 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $883.81 | 63 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $798.59 | 60 | $0 (2020) |
| Allergan, Inc. | $790.70 | 65 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $701.10 | 83 | $0 (2020) |
| Novo Nordisk Inc | $305.11 | 13 | $0 (2024) |
| Dr.Reddy's Laboratories,Inc. | $267.00 | 1 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $239.31 | 12 | $0 (2021) |
| LivaNova USA, Inc. | $173.58 | 9 | $0 (2020) |
| Eisai Inc. | $172.94 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $188.11 | 5 | Novo Nordisk Inc ($154.86) |
| 2023 | $3,937 | 9 | Eli Lilly and Company ($3,723) |
| 2022 | $36,986 | 7 | Eli Lilly and Company ($36,892) |
| 2021 | $168.76 | 8 | Allergan, Inc. ($50.05) |
| 2020 | $1,085 | 73 | Teva Pharmaceuticals USA, Inc. ($237.96) |
| 2019 | $1,520 | 118 | Sunovion Pharmaceuticals Inc. ($277.00) |
| 2018 | $1,391 | 92 | Sunovion Pharmaceuticals Inc. ($267.10) |
| 2017 | $1,883 | 105 | Eli Lilly and Company ($721.75) |
All Payment Transactions
417 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $119.70 | General |
| 06/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: Respiratory | ||||||
| 02/02/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $9.18 | General |
| Category: Obesity | ||||||
| 01/29/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $15.22 | General |
| 01/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $10.76 | General |
| Category: Obesity | ||||||
| 11/28/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $119.00 | General |
| Category: Neurology | ||||||
| 09/22/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Obesity | ||||||
| 06/08/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: Diabetes | ||||||
| 05/23/2023 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: Neuroscience | ||||||
| 05/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $303.08 | Research |
| Study: ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 04/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $1,373.52 | Research |
| Study: ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 04/10/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Obesity | ||||||
| 02/06/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Obesity | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $2,046.15 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 12/19/2022 | EISAI INC. | — | Education | Cash or cash equivalent | $30.00 | General |
| 11/01/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $33,281.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 10/04/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.38 | General |
| Category: Diabetes | ||||||
| 08/11/2022 | ABBVIE INC. | DUOPA (Drug) | Food and Beverage | In-kind items and services | $21.15 | General |
| Category: NEUROSCIENCE | ||||||
| 06/21/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: NEUROSCIENCE | ||||||
| 04/19/2022 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Neuroscience | ||||||
| 02/25/2022 | Eli Lilly and Company | — | — | In-kind items and services | $3,611.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 12/02/2021 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: Obesity | ||||||
| 07/29/2021 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: HYPERHYDROSIS | ||||||
| 06/30/2021 | Biogen, Inc. | ADUHELM (Biological) | Education | In-kind items and services | $43.17 | General |
| Category: NEUROLOGY | ||||||
| 06/14/2021 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $11.09 | General |
| Category: Obesity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $36,892 | 2 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $2,046 | 1 |
| ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,374 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $721.75 | 1 |
| ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $303.08 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 483 | 533 | $179,077 | $42,992 |
| 2022 | 4 | 472 | 521 | $183,799 | $48,473 |
| 2021 | 5 | 291 | 301 | $116,380 | $32,729 |
| 2020 | 9 | 486 | 543 | $113,396 | $39,813 |
Total Patients
1,732
Total Services
1,898
Medicare Billing
$164,008
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 239 | 286 | $87,460 | $21,452 | 24.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 114 | 114 | $53,308 | $11,449 | 21.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 47 | 48 | $19,838 | $5,229 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 56 | $11,623 | $2,999 | 25.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $6,490 | $1,712 | 26.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 17 | 18 | $358.00 | $151.20 | 42.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 167 | 204 | $62,220 | $17,198 | 27.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 149 | 149 | $69,583 | $16,099 | 23.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 82 | 84 | $34,608 | $10,407 | 30.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 74 | 84 | $17,388 | $4,769 | 27.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 104 | 104 | $48,568 | $11,922 | 24.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 84 | 91 | $27,755 | $8,867 | 31.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 51 | $21,012 | $6,567 | 31.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 20 | 20 | $11,800 | $2,922 | 24.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 32 | 35 | $7,245 | $2,451 | 33.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 204 | 233 | $47,066 | $14,661 | 31.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 82 | 82 | $25,420 | $9,226 | 36.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 29 | 29 | $11,281 | $4,602 | 40.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 78 | 84 | $11,508 | $3,887 | 33.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 16 | 16 | $6,256 | $2,504 | 40.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 32 | 42 | $5,838 | $2,373 | 40.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 22 | 33 | $2,475 | $1,016 | 41.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 12 | 12 | $1,848 | $1,005 | 54.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 11 | 12 | $1,704 | $537.69 | 31.6% |
About Dr. Gregory Cooper, M.D
Dr. Gregory Cooper, M.D is a Sleep Medicine healthcare provider based in Louisville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265466627.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Cooper, M.D has received a total of $47,159 in payments from pharmaceutical and medical device companies, with $188.11 received in 2024. These payments were reported across 417 transactions from 37 companies. The most common payment nature is "" ($41,337).
As a Medicare-enrolled provider, Cooper has provided services to 1,732 Medicare beneficiaries, totaling 1,898 services with total Medicare billing of $164,008. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Other Specialties Neurology
- Location Louisville, KY
- Active Since 07/10/2006
- Last Updated 03/09/2021
- Taxonomy Code 2084S0012X
- Entity Type Individual
- NPI Number 1265466627
Products in Payments
- TROKENDI XR (Drug) $883.81
- APTIOM (Drug) $798.59
- BOTOX (Biological) $458.92
- AJOVY (Drug) $259.26
- VNS Therapy (Device) $240.42
- AUSTEDO (Drug) $195.48
- Aimovig (Biological) $147.96
- AJOVY (Biological) $146.68
- NAMZARIC (Drug) $137.82
- AIMOVIG (Biological) $122.10
- Leqembi (Drug) $119.00
- RYTARY (Drug) $115.61
- Nucynta (Drug) $104.24
- Wegovy (Drug) $103.76
- TEGSEDI (Drug) $100.44
- COPAXONE (Drug) $99.68
- MAYZENT (Drug) $92.91
- Gralise (Drug) $92.32
- Gamunex-C (Biological) $79.52
- NUPLAZID (Drug) $63.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Sleep Medicine Doctors in Louisville
Karim El-Kersh, Md, MD
Sleep Medicine — Payments: $199,588
Sleep Medicine $199,588
Dr. Josephine Mei, Md, MD
Sleep Medicine — Payments: $102,719
Sleep Medicine $102,719
Dr. David Hasselbacher, M.d, M.D
Sleep Medicine — Payments: $18,304
Sleep Medicine $18,304
Sarika Chandiramani
Sleep Medicine — Payments: $1,428
Sleep Medicine $1,428
Courtney Minor, Md, MD
Sleep Medicine — Payments: $860.20
Sleep Medicine $860.20
Emily Singer, M.d, M.D
Sleep Medicine — Payments: $324.41
Sleep Medicine $324.41